Intra-Cellular Therapies Inc.

ITCI | $73.02 -1.34% -1.36% 730K

(0.0% 1d) (8.6% 1m) (19.8% 1y) (0.0% 2d) (-1.2% 3d) (1.0% 7d) (-10.9% volume)
Earnings Calendar: 2024-02-22
Market Cap: $ 7,068,861,087
http://www.intracellulartherapies.com
Sec Filling | Patents | 330 employees

Intra-Cellular Therapies, Inc. is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY.

neurodegenerative schizophrenia glass alzheimer heavy drug nervous system neuropsychiatric molecule drugs neurological msa treatment alzheimer’s

add to watch list Paper trade email alert is off

Press-releases

Intra-Cellular Therapies Announces Closing of $575 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Published: 2024-04-24 (Crawled : 20:00) - globenewswire.com
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| Email alert Add to watchlist
MS | News | $93.85 0.1% 0.0% 4.8M

Finance

| Email alert Add to watchlist
million offering

Intra-Cellular Therapies Prices Public Offering of Common Stock
Published: 2024-04-18 (Crawled : 01:00) - globenewswire.com
MS | News | $93.85 0.1% 0.0% 4.8M

Finance

| 3.94% | O: 0.43% H: 0.0% C: 0.0%
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| -6.21% | O: -4.8% H: 0.0% C: 0.0%
offering

Intra-Cellular Therapies Prices Public Offering of Common Stock - April 18, 2024
Published: 2024-04-18 (Crawled : 06:00) - biospace.com/
MS | News | $93.85 0.1% 0.0% 4.8M

Finance

| 3.94% | O: 0.43% H: 0.0% C: 0.0%
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| -6.21% | O: -4.8% H: 0.0% C: 0.0%
offering

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock
Published: 2024-04-16 (Crawled : 20:00) - globenewswire.com
MS | News | $93.85 0.1% 0.0% 4.8M

Finance

| 3.79% | O: -0.14% H: 0.0% C: 0.0%
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| -8.42% | O: -2.35% H: 0.0% C: 0.0%
offering

Intra-Cellular Therapies Announces Positive Phase 3 Topline Results from Study 501 Evaluating Lumateperone as Adjunctive Therapy in Patients with Major Depressive Disorder
Published: 2024-04-16 (Crawled : 11:00) - globenewswire.com
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| 11.45% | O: 14.75% H: 12.75% C: 6.04%
positive topline therapy results study

Intra-Cellular Therapies Announces Executive Appointments and Leadership Changes
Published: 2024-03-19 (Crawled : 12:30) - globenewswire.com
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| 11.86% | O: -2.23% H: 4.32% C: 2.41%

Intra-Cellular Therapies to Participate in Three Upcoming Investor Conferences
Published: 2024-03-06 (Crawled : 13:00) - globenewswire.com
ITCI | $73.02 -1.34% -1.36% 730K

Health Technology

| 9.76% | O: 1.17% H: 0.83% C: -2.03%